FRISCO, TX—(Marketwired – January 13, 2016) – OxySure Therapeutics, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), a global leader and medical device innovator of life–saving, easy–to–use emergency oxygen products with its “oxygen from powder” technology and other innovative medical solutions today announced that Dr. Zachariah P. Zachariah, a former Director of Ivax Corporation (together with its Chairman Dr. Phil Frost) will be joining OxySure's Strategic Advisory Board effective immediately. Ivax, a marketer of a patented asthma inhaler called Easi–Breathe and other branded respiratory drugs, was acquired by Teva Pharmaceutical Industries for $7.4 billion.
Dr. Zachariah is a prominent cardiologist, philanthropist, humanitarian, business and community leader and has been in Private Practice of Clinical and Interventional Cardiology at Holy Cross Hospital, Fort Lauderdale, since 1976. Dr. Zachariah is the President of the Fort Lauderdale Heart Institute, serves as the Section Chief of Cardiology at Holy Cross Hospital, and is currently a Voluntary Clinical Professor of Medicine at the University of Miami School of Medicine.
Dr. Zachariah has served as a member of the Board of Trustees of Nova Southeastern University since 1993; Treasurer and Member of the Board of the Foundation for Excellence in Education; a member and former President of the Florida Council on Economic Education, a not–for–profit organization that educates students in kindergarten through high school on economic principles to better prepare them for personal and professional success in our free enterprise system; and he is a member of The Florida Council of 100, a statewide organization of business leaders who advise the Governor on issues of public policy.
Dr. Zachariah currently serves on the Florida Board of Medicine, having previously served from 1988 to 1992 and again from 1998 and 2002. He served as Chairman of the Board of Medicine from 1990–1992, from 2001–2002 and again from 2013–2014. From 2003–2010, he served on the Florida Board of Governors which oversees all public universities in the State of Florida; and was Chairman of the Governor's Task Force on the Obesity Epidemic in 2003. He has also served as the President of the American Heart Association – Florida Affiliate and as a Member of the Board of Governors for the Florida Medical Association.
Dr. Zachariah has also served as a member of the National Heart, Lung and Blood Advisory Council of the National Institutes of Health from 1990 – 1993, under President George H.W. Bush, and as a member of the President's Advisory Commission on Asian American and Pacific Islanders in 2001 – 2005 under President George W. Bush. He also served as Special Advisor to the Secretary of Health and Human Services at the World Health Organization in Geneva, Switzerland in May 2002.
Dr. Zachariah has received numerous awards for his humanitarian work, community service, advocacy on behalf of children and his leadership in public health. He was awarded the “Ellis Island Medal of Honor” in 1988; the “Ellis Island American Legends Award” from the National Ethnic Coalition of Organizations Foundations, Inc.; in 2000 the “George Washington Honor Medal” from the Freedoms Foundation at Valley Forge; and the “Torch of Liberty Award” from the American Jewish Congress. Three Florida Governors, have proclaimed a “Zachariah P. Zachariah Day” in the State of Florida.
Dr. Zachariah graduated from the Armed Forces Medical College in Poona, India; completed a residency in internal medicine at St. Joseph's Hospital and Medical Center in Paterson, New Jersey, and had a Fellowship in Cardiology at the Cleveland Clinic Educational Foundation in Cleveland, Ohio. He has performed in excess of 25,000 heart procedures since he started his career at Holy Cross Hospital.
Speaking from the JP Morgan Healthcare conference in San Francisco Julian Ross, Chairman and CEO of OxySure stated: “We are delighted to have Zach join our team, and we very much look forward to working together to grow our business, enhance shareholder value, improve medical outcomes with our innovative products, and save lives.”
Dr. Zachariah commented: “I am pleased to join the OxySure Advisory Board and I look forward to assisting Julian and his team as they develop this business globally. I believe OxySure is a game changer and a no–brainer as a companion product to Automated External Defibrillators (AEDs) for post–resuscitation usage by lay rescuers in cardiac arrest events.”
About OxySure Therapeutics, Inc.
OxySure Therapeutics, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen–deficient situations in industrial, mining, military, or other “Immediately Dangerous to Life or Health” (IDLH) environments. In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products. www.OxySure.com
Forward–Looking Statements
Statements in this earnings release that are not historical facts are considered to be forward–looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward–looking statements are subject to risks and uncertainties, many of which are beyond management's control and actual results and performance may differ significantly from those contained in forward–looking statements. OxySure Therapeutics, Inc. intends any forward–looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said safe harbor provisions. Readers are cautioned not to place undue reliance on forward–looking statements, which speak only as of the date of this news release. OxySure Therapeutics, Inc. undertakes no obligation to update any forward–looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward–looking statements is included in OxySure Therapeutics, Inc.'s Annual Report on Form 10–K for the year ended December 31, 2014.
The following files are available for download:
PDF